{
  "Cancer Histology Type (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3339, 
        3353
      ]
    }
  ], 
  "Clinical History Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3857, 
        3880
      ]
    }
  ], 
  "Final Diagnosis Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2680, 
        2707
      ]
    }
  ], 
  "Macroscopic/Gross Description Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        422, 
        451
      ]
    }
  ], 
  "Microscopic Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2179, 
        2214
      ]
    }
  ], 
  "Neoplasm Behaviour (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2753, 
        2759
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3146, 
        3152
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3320, 
        3328
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3493, 
        3499
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3682, 
        3688
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3755, 
        3761
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3827, 
        3833
      ]
    }
  ], 
  "Organ/Body Structure (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2760, 
        2776
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3153, 
        3169
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3329, 
        3338
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3500, 
        3516
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3689, 
        3705
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3762, 
        3778
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3834, 
        3850
      ]
    }
  ], 
  "Relative Location (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2729, 
        2739
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2802, 
        2812
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2904, 
        2913
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3013, 
        3022
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3122, 
        3132
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3195, 
        3205
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3297, 
        3306
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3471, 
        3480
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3542, 
        3550
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3661, 
        3669
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3732, 
        3741
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3805, 
        3814
      ]
    }
  ], 
  "Specimen Identifier (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2709, 
        2710
      ]
    }
  ], 
  "__text": "MSH|^~\\&|PATHLAB_LIS|HOSPITAL 11^9311^MOH|PIMS|CCO|20160511112725|A85A9D8A1D8B480AFF287A54FEE0F15AC36DC6DE|ORU^R01|99999999999999999999|P|2.5|||||\nPID|1||^^^^MRN^HOSPITAL 11&9999&MOH~9999999999&TT&ON^^^^JHN||XXXXX^XXXXX^||99999999|M||||||||||||||||||||||N|\nOBR|1||BZ00604719|11529-5^Surgical Pathology Study Report^LN^BX^Biopsy^L|||20160428|||50822^XXXXXXXX XXXXXXXXXX^XXXXXXX^^^XX.||||||||||||20160511|||F||||||||\n\n\n\n\n\n\n\nPath report.gross description\n\n1.Specimen consists of 1 tan tissue corenE\\measuring 13 mm in length by less than 1 mm innE\\diameter and no fragments. Embedded in toto.nE\nE\\2.Specimen consists of 1 tan tissue corenE\\measuring 16 mm in length by less than 1 mm innE\\diameter and no fragments. Embedded in toto.nE\nE\\3.Specimen consists of 1 tan tissue corenE\\measuring 16 mm in length by less than 1 mm innE\\diameter and no fragments. Embedded in toto.nE\nE\\4.Specimen consists of 1 tan tissue corenE\\measuring 20 mm in length by less than 1 mm innE\\diameter and no fragments. Embedded in toto.nE\nE\\5.Specimen consists of 1 tan tissue corenE\\measuring 15 mm in length by less than 1 mm innE\\diameter and no fragments. Embedded in toto.nE\nE\\6.Specimen consists of 1 tan tissue corenE\\measuring 20 mm in length by less than 1 mm innE\\diameter and no fragments. Embedded in toto.nE\nE\\7.Specimen consists of 1 tan tissue corenE\\measuring 15 mm and 1 fragment measuring in totalnE\\1 mm in length by less than 1 mm in diameter.nE\\Embedded in toto.nE\nE\\8.Specimen consists of 1 tan tissue corenE\\measuring 20 mm in length by less than 1 mm innE\\diameter and no fragments. Embedded in toto.nE\nE\\9.Specimen consists of 1 tan tissue corenE\\measuring 16 mm in length by less than 1 mm innE\\diameter and no fragments. Embedded in toto.nE\nE\\10.Specimen consists of 1 tan tissue corenE\\measuring 21 mm in length by less than 1 mm innE\\diameter and no fragments. Embedded in toto.nE\nE\\11.Specimen consists of 1 tan tissue corenE\\measuring 21 mm in length by less than 1 mm innE\\diameter and no fragments. Embedded in toto.nE\nE\\12.Specimen consists of 2 tan tissue coresnE\\each measuring 10 mm in length by less than 1 mmnE\\in diameter and no fragments. Embedded in toto.nE\\\n\n\nPath report.microscopic observation\n\nTumour TypenE\\Adenocarcinoma, conventional typenE\nE\\ExtentnE\\# sites involved/total sites  1 / 12nE\\# cores involved/total cores  1 / 12nE\\Overall % tissue involved <2%nE\\% involvement in mostnE\\extensively involved core  20%nE\nE\\GleasonnE\\Overall Gleason Score (1?, worst)7 (4, 3)nE\\Highest Gleason Score (any site)7 (4, 3)nE\\% Gleason patterns 4, 5  \\R\\50-60%.nE\nE\\OthernE\\Perineural invasion     Not identifiednE\\Periprostatic fat invasion  Not identifiednE\\\n\n\nPath report.final diagnosis\n\n1.BIOPSY, PROSTATE (RIGHT BASE LATERAL)nE\\- BENIGN PROSTATIC TISSUE.nE\nE\\2.BIOPSY, PROSTATE (RIGHT BASE MEDIAL)nE\\- FOCAL CHRONIC INFLAMMATION, NEGATIVE FORnE\\MALIGNANCY.nE\nE\\3.BIOPSY, PROSTATE (RIGHT MID LATERAL)nE\\- FOCAL ACTIVE CHRONIC INFLAMMATION, NEGATIVE FORnE\\MALIGNANCY.nE\nE\\4.BIOPSY, PROSTATE (RIGHT MID MEDIAL)nE\\- FOCAL PROSTATIC INTRAEPITHELIAL NEOPLASIAnE\\(PIN), HIGH GRADE.nE\nE\\5.BIOPSY, PROSTATE (RIGHT APEX LATERAL)nE\\- BENIGN PROSTATIC TISSUE.nE\nE\\6.BIOPSY, PROSTATE (RIGHT APEX MEDIAL)nE\\- FOCAL CHRONIC INFLAMMATION, NEGATIVE FORnE\\MALIGNANCY.nE\nE\\7.BIOPSY, PROSTATE (LEFT BASE LATERAL)nE\\- INVASIVE PROSTATIC ADENOCARCINOMA; GLEASONnE\\SCORE 7/10 (PRIMARY 4, SECONDARY 3); 1/1 COREnE\\INVOLVED; 20% TISSUE INVOLVEMENT.nE\nE\\8.BIOPSY, PROSTATE (LEFT BASE MEDIAL)nE\\- BENIGN PROSTATIC TISSUE.nE\nE\\9.BIOPSY, PROSTATE (LEFT MID LATERAL)nE\\- FOCAL ATYPICAL SMALL ACINAR PATTERN (ASAP) OFnE\\UNCERTAIN SIGNIFICANCE.nE\nE\\10.BIOPSY, PROSTATE (LEFT MID MEDIAL)nE\\- BENIGN PROSTATIC TISSUE.nE\nE\\11.BIOPSY, PROSTATE (LEFT APEX LATERAL)nE\\- BENIGN PROSTATIC TISSUE.nE\nE\\12.BIOPSY, PROSTATE (LEFT APEX MEDIAL)nE\\- BENIGN PROSTATIC TISSUE.nE\\\n\n\nPath report.relevant Hx\n\nPSA Total: 4.8 ng/mLnE\\Ratio: 9%nE\\5ARI Therapy (past 6 months): NonE\\DRE Findings:  BPHnE\\Volume (cc):  39nE\\TRUS Findings:  NegativenE\nE\\Previous Bx: 2011, negativenE\\\n\n\n"
}